Life Science Nation Newsletter | April 21, 2016 | Issue 159
|
|
 Life Science Investor Mandates (Apr. 14 - Apr. 20) |
| |
|
Seeks Therapeutics & Devices in the EU and US
|
Seeks CNS, Infection, Oncology and Immunology Deals
|
|
Raises New Fund to Invest in Digital Health and Medical Devices
|
|
Invests in Medtech, HCIT, and Medical Data and AI Technology
|
|
|
By Dianne Carmichael, Guest Writer; Managing Director, Health Innovation & Venture Services, MaRS Discovery District
Blog Post Series #2 of 3
 Toronto is poised to be a super hub of health. The reason: The old in-house research model of big pharma is being augmented by more aggressive partnering and co-development, part of a new outsourcing strategy for everything from drugs to medical devices.
Toronto did not fare well under the old model. In its heyday, labs such as Merck in Montreal had an annual budget of approximately $90 million and employed 300 people in Quebec. Rarely did big pharma engage with the kinds of smaller R&D firms which are plentiful in Toronto's Discovery District...
|
 |
|
|
LSN is gearing up for our first international RESI event in Toronto on June 23rd, and we're seeking the most promising early stage healthcare technologies to showcase in the MaRS HealthKick Innovation Challenge. Successful applicants will be showcased in an exhibition-style format throughout the full-day conference.
LSN's internal scientific review board will choose the top 30 applicant companies to present their technologies. Presenters will gain exposure to investors and potential partners by showcasing their companies and products in a poster board format in the RESI Exhibition Hall. Unlike traditional 5- to 15-minute pitch presentations...
|
|
 Everything's bigger in Texas, and according to one investor's number-crunching, that includes med tech valuations. Steve Banks (Emeritus Venture Partner, S3 Ventures) has provided LSN with a short presentation that explores the current med tech investment landscape in Texas and the USA as a whole.
The presentation covers med tech financing trends, looking at capital invested, the number of deals made, and some notable investments and exits. While the amount of capital invested in US med tech companies has been stable in the last two years, the number of deals is declining, thus making it more important than ever to ensure that your company is being proactive about connecting with investors who are a good fit...
|
|
|
|
|
